
PhD ceremony Ms. M.K.S. van Duijl-Richter: Dengue and Chikungunya Virus. Cell entry mechanisms and the impact of antibodies on infectivity
PhD ceremony: Ms. M.K.S. van Duijl-Richter, 11.00hrs, Academiegebouw, Broerstraat 5, Groningen
Dissertation: Dengue and Chikungunya Virus. Cell Entry Mechanisms and the Impact of Antibodies on Infectivity
Promotor(s): prof.dr. J.M. Smit, prof.dr. A.M. van Oijen
Faculty: Medical Sciences / UMCG
Summary:
Dengue virus (DENV) and Chikungunya virus (CHIKV) are rapidly emerging viruses that are prevalent in the tropical and subtropical regions of world. Both viruses are transmitted to humans by mosquitoes of the Aedes species, which include the yellow fever mosquito and the Asian tiger mosquito. DENV can cause dengue fever, which is characterized by flu-like symptoms. Also, yearly about 500,000 patients develop more severe dengue, which can be fatal if not properly treated.
CHIKV causes chikungunya fever, with symptoms including high fever, rash, headache, and muscle and joint pain. Approximately 12-49% of CHIKV-infected patients develop chronic debilitating joint pain, which persists from months to years. No specific antiviral treatment or vaccine is available for either of the viruses and treatment is focused on relieving the disease symptoms. For the rational design of vaccines and antiviral drugs it is imperative to better understand the dynamic interactions that occur between the virus and the host during virus reproduction.
The research described in this thesis focuses on the early events in DENV and CHIKV infection. We aimed to further investigate the molecular mechanisms that are involved in viral cell entry. For DENV, we focused on the role of the viral precursor membrane (prM) protein in virus infectivity and how antibodies control the infectious properties of the virus. For CHIKV, we dissected the viral entry pathway and the molecular mechanisms of viral membrane fusion. In addition, we investigated the working mechanism of potent, fusion-inhibitory antibodies against CHIKV.
Last modified: | 02 February 2016 2.05 p.m. |
More news
-
11 February 2025
Space for your disability
When it comes to collaborations between researchers from different faculties, the UG is at the top of its game. A prime example is the Disabled City project that researches how the mobility of people with a physical disability can be explored...
-
16 January 2025
€16,5 miljoen subsidie voor onderzoek naar effect CAR T-cellen bij terugkerende beenmergkanker
Het UMCG gaat specifieke CAR-T cellen produceren om patiënten met terugkerende beenmergkanker te behandelen. Samen met Amsterdam UMC Cancer Center Amsterdam gaat het UMCG de effectiviteit van deze mogelijk nieuwe behandeling onderzoeken. Voor het...
-
27 August 2024
UMCG gaat onderzoeksfaciliteiten beschikbaar stellen voor geneesmiddelenontwikkeling
Om de beschikbaarheid en effectiviteit van geneesmiddelen in Nederland te verbeteren gaat het UMCG het bedrijf G² Solutions opzetten. Dit bedrijf moet ervoor gaan zorgen dat belangrijke technologische ontwikkelingen op het gebied van DNA sequencing...